Acceder

Publicaciones - CARDIOLOGIA CLINICA Y EXPERIMENTAL

Cargando...
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Peil B, Nordaby M, Brueckmann M, Pocock SJ, Zannad F, Packer M; EMPEROR-Reduced trial committees and investigators. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022 Jan;10(1):35-45. doi: 10.1016/S2213-8587(21)00292-8. Epub 2021 Nov 30. PubMed PMID: 34861154.
AÑO: 2022; IF: 44.5
34861154
Sanchez-Camara S, Asensio-Lopez MC, Royo-Villanova M, Soler F, Jara-Rubio R, Garrido-Penalver JF, Pinar E, Hernandez-Vicente A, Hurtado JA, Lax A, Pascual-Figal DA. Critical warm ischemia time point for cardiac donation after circulatory death. Am J Transplant. 2022 May;22(5):1321-1328. doi: 10.1111/ajt.16987. Epub 2022 Feb 21. PubMed PMID: 35114047; PubMed Central PMCID: PMC9303247.
AÑO: 2022; IF: 8.8
35114047
Delgado-Jimenez JF, Segovia-Cubero J, Almenar-Bonet L, de Juan-Baguda J, Lara-Padron A, Garcia-Pinilla JM, Bonilla-Palomas JL, Lopez-Fernandez S, Mirabet-Perez S, Gomez-Otero I, Castro-Fernandez A, Diaz-Molina B, Goirigolzarri-Artaza J, Rincon-Diaz LM, Pascual-Figal DA, Anguita-Sanchez M, Muniz J, Crespo-Leiro MG. Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics. J Clin Med. 2022 Feb 22;11(5):1170. doi: 10.3390/jcm11051170. PubMed PMID: 35268260; PubMed Central PMCID: PMC8910891.
AÑO: 2022; IF: 4.964
35268260
Wiebe J, Hofmann FJ, West N, Baumbach A, Carrie D, Bermudez EP, Cayla G, Hernandez FH, de la Torre Hernandez JM, Koning R, Loi B, Moscarella E, Tarantini G, Zaman A, Lober C, Riemer T, Achenbach S, Hamm CW, Nef HM; European ABSORB Consortium (EAC) investigators. Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice - results from the European Absorb Consortium. Catheter Cardiovasc Interv. 2022 Feb;99(3):533-540. doi: 10.1002/ccd.29932. Epub 2021 Aug 31. PubMed PMID: 34463427.
AÑO: 2022; IF: 2.3
34463427
Patti G, D'Ascenzo F, De Filippo O, Bruno F, Leonardi S, Chieffo A, Iannaccone M, Liebetrau C, Manzano-Fernandez S, Gallone G, Omede P, Cerrato E, Kinnaird T, Conrotto F, Piroli F, Henriques JPS, Wanha W, Elia E, Dominguez-Rodriguez A, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM; PRAISE Study Group. Safety and efficacy of different P2Y12 inhibitors in patients with acute coronary syndromes stratified by the PRAISE risk score: a multicentre study. Eur Heart J Qual Care Clin Outcomes. 2022 Nov 17;8(8):881-891. doi: 10.1093/ehjqcco/qcac002. PubMed PMID: 35022719.
AÑO: 2022; IF: 5.2
35022719
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

CARDIOLOGIA CLINICA Y EXPERIMENTAL